{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:33Z","timestamp":1791379473019,"version":"4.3.2"},"reference-count":48,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose\nIndividuals with Bipolar II disorder (BD-II) face high rates of depression and have limited FDA-approved treatments, leading to treatment delays and poor functioning. Although not commonly recommended, monoaminergic antidepressants are prescribed to 50% of patients. This review updates the evidence for second-generation antidepressant (SGAD) monotherapy in treating acute BD-II depression.\nMethods\nWe searched Ovid MEDLINE, Embase, CENTRAL, PsycINFO, Scopus, and Web of Science from March 2021 to February 2025 and included five studies published before 2021. Randomized controlled trials (RCTs) evaluating SGAD monotherapy in adults with acute BD-II depression. Primary outcomes were response, remission, treatment-emergent affective switch (TEAS), dropouts owing to adverse events (AEs), and overall discontinuations.\nResults\nOf 949 records identified, 12 studies were selected for full-text assessment, and six were included in our systematic review. The final dataset comprised four double-blind RCTs (n = 533), one open-label RCT (n = 83), and one triple-blind RCT (n = 40). Venlafaxine and sertraline produced short-term benefits, with response rates 60.4%\u201373.3% and remission rates 44.2%\u201358.5%. TEAS risk was \u2a7d 19.9% and did not differ from lithium in head-to-head comparisons. AEs withdrawals were similar; SGADs often had comparable or better all-cause discontinuation than comparators.\nConclusions\nLimited short-term evidence indicates that SGAD monotherapy in acute BD-II depression is well-tolerated and has similar response rates to lithium, without increasing switch risk. Nevertheless, the evidence base is small and heterogeneous. Larger and longer RCTs are needed to confirm efficacy, characterize maintenance benefits, and inform personalized treatment decisions.<\/jats:p>","DOI":"10.64719\/pb.4545","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"79-103","source":"Crossref","is-referenced-by-count":5,"title":["Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression"],"prefix":"10.64719","volume":"55","author":[{"given":"Ahmed","family":"Elmosalamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Keeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J","family":"Gerberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Angst J, Gamma A, Bowden CL et al. Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the Bridge Study: validity and comorbidity. Eur Arch Psychiatry Clin Neurosci. 2013;263(8):663\u2013673. doi: 10.1007\/s00406-013-0393-4.","DOI":"10.1007\/s00406-013-0393-4"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Citrome L. Food and drug administration-approved treatments for acute bipolar depression: what we have and what we need. Journal of Clinical Psychopharmacology. 2020;40(4):334\u2013338.","DOI":"10.1097\/JCP.0000000000001227"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord. 2003;5(6):388\u2013395. doi: 10.1046\/j.1399-5618.2003.00066.x.","DOI":"10.1046\/j.1399-5618.2003.00066.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Fletcher K, Parker G, Manicavasagar V. A qualitative investigation of hypomania and depression in bipolar II disorder. Psychiatr Q. 2013;84(4):455\u2013474. doi: 10.1007\/s11126-013-9259-1.","DOI":"10.1007\/s11126-013-9259-1"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Parker G, Tavella G, Ricciardi T et al. Refined diagnostic criteria for the bipolar disorders: phase two of the AREDOC project. Acta Psychiatr Scand. 2020;142(3):193\u2013202. doi: 10.1111\/acps.13218.","DOI":"10.1111\/acps.13218"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bopp JM, Miklowitz DJ, Goodwin GM, Stevens W, Rendell JM, Geddes JR. The longitudinal course of bipolar disorder as revealed through weekly text messaging: a feasibility study. Bipolar Disord. 2010;12(3):327\u2013334. doi: 10.1111\/j.1399-5618.2010.00807.x.","DOI":"10.1111\/j.1399-5618.2010.00807.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530\u20137. doi: 10.1001\/archpsyc.59.6.530.","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Gitlin M, Malhi GS. The existential crisis of bipolar II disorder. Int J Bipolar Disord. 2020;8(1):5. doi: 10.1186\/s40345-019-0175-7.","DOI":"10.1186\/s40345-019-0175-7"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar i and bipolar II disorder. World Journal of Biological Psychiatry. 2014;15(2):96\u2013112.","DOI":"10.3109\/15622975.2012.665177"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Swartz HA, Suppes T. Bipolar II disorder: understudied and underdiagnosed. Focus. 2023;21(4):354\u2013362.","DOI":"10.1176\/appi.focus.20230015"},{"key":"ref11","unstructured":"Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry. 1976;11(1):31\u201342."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"DePaulo JR, Jr, Simpson SG, Gayle JO, Folstein SE. Bipolar II disorder in six sisters. J Affect Disord. 1990;19(4):259\u2013264. doi: 10.1016\/0165-0327(90)90103-f.","DOI":"10.1016\/0165-0327(90)90103-f"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Dunner DL. Bipolar disorders in DSM-IV: impact of inclusion of rapid cycling as a course modifier. Neuropsychopharmacology. 1998;19(3):189\u2013193. doi: 10.1016\/s0893-133x(98)00024-4.","DOI":"10.1016\/s0893-133x(98)00024-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Plans L, Barrot C, Nieto E et al. Association between completed suicide and bipolar disorder: A systematic review of the literature. J Affect Disord. 2019;242:111\u2013122. doi: 10.1016\/j.jad.2018.08.054.","DOI":"10.1016\/j.jad.2018.08.054"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Dev DA, Le GH, Kwan ATH et al. Comparing suicide completion rates in bipolar I versus bipolar II disorder: a systematic review and meta-analysis. J Affect Disord. 2024;361:480\u2013488. doi: 10.1016\/j.jad.2024.06.045.","DOI":"10.1016\/j.jad.2024.06.045"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hert MD, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry. 2011;26:144\u2013158.","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ferensztajn-Rochowiak E, Rybakowski JK. Long-term lithium therapy: side effects and interactions. Pharmaceuticals. 2023;16(1):74.","DOI":"10.3390\/ph16010074"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Young AH, Calabrese JR, Gustafsson U et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord. 2013;1:10. doi: 10.1186\/2194-7511-1-10.","DOI":"10.1186\/2194-7511-1-10"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tarzian M, Ndrio M, Chique B et al. Illuminating hope for mental health: a drug review on lumateperone. Cureus. 2023;15(9):e46143. doi: 10.7759\/cureus.46143.","DOI":"10.7759\/cureus.46143"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Pacchiarotti I, Bond DJ, Baldessarini RJ et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249\u20131262. doi: 10.1176\/appi.ajp.2013.13020185.","DOI":"10.1176\/appi.ajp.2013.13020185"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry. 2004;161(9):1537\u20131547. doi: 10.1176\/appi.ajp.161.9.1537.","DOI":"10.1176\/appi.ajp.161.9.1537"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170. doi: 10.1111\/bdi.12609.","DOI":"10.1111\/bdi.12609"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Hooshmand F, Do D, Shah S et al. Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients. Journal of Affective Disorders. 2018;234:74\u201379. doi: 10.1016\/j.jad.2018.02.091.","DOI":"10.1016\/j.jad.2018.02.091"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Koistinaho A, Poranen J, Tanskanen A, Tiihonen J, Taipale H, L\u00e4hteenvuo M. Real-world use of pharmacological treatments for incident bipolar disorder: a finnish nationwide cohort study. J Affect Disord. 2023;340:237\u2013244. doi: 10.1016\/j.jad.2023.08.015.","DOI":"10.1016\/j.jad.2023.08.015"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Park JH, Nunez NA, Gardea-Resendez M et al. Short term second-generation antidepressant monotherapy in acute depressive episodes of bipolar II disorder: a systematic review and meta-analysis. Psychopharmacology Bulletin. 2022;52(2):45\u201372.","DOI":"10.64719\/pb.4433"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Fakhri A, Asadi K, Pakseresht S, Norouzi S, Rostami H. Comparison of the efficacy of venlafaxine and bupropion in the treatment of depressive episode in patients with bipolar II disorder. Journal of Family Medicine and Primary care. 2023;12(3):440\u2013445. doi: 10.4103\/jfmpc.jfmpc_1258_22.","DOI":"10.4103\/jfmpc.jfmpc_1258_22"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"McElroy SL, Weisler RH, Chang W et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry. 2010;71(2):163\u2013174. doi: 10.4088\/JCP.08m04942gre.","DOI":"10.4088\/JCP.08m04942gre"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II disorder? A proof of concept study. J Affect Disord. 2006;92(2\u20133):205\u2013214. doi: 10.1016\/j.jad.2006.01.024.","DOI":"10.1016\/j.jad.2006.01.024"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry. 2016;208(4):359\u2013365. doi: 10.1192\/bjp.bp.115.169375.","DOI":"10.1192\/bjp.bp.115.169375"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Altshuler LL, Sugar CA, McElroy SL et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. Am J Psychiatry. 2017;174(3):266\u2013276. doi: 10.1176\/appi.ajp.2016.15040558.","DOI":"10.1176\/appi.ajp.2016.15040558"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008;28(2):171\u2013181. doi: 10.1097\/JCP.0b013e318166c4e6.","DOI":"10.1097\/JCP.0b013e318166c4e6"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Fredskild MU, Bruun CF, Vinberg M, Faurholt-Jepsen M, Kessing LV, Munkholm K. Lithium and lamotrigine for the treatment of bipolar II disorder\u2013a systematic review and meta-analysis of randomized trials. J Affect Disord. 2025 doi: 10.1016\/j.jad.2025.04.125.","DOI":"10.1016\/j.jad.2025.04.125"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Jefsen OH, Rohde C, Ostergaard SD. Revisiting the association between treatment with antidepressants and mania: a nationwide within-individual study of 3554 patients with bipolar disorder. Bipolar Disorders. 2023;25(7):583\u2013591. doi: 10.1111\/bdi.13353.","DOI":"10.1111\/bdi.13353"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Bond DJ, Noronha MM, Kauer-Sant\u2019Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589\u20131601. doi: 10.4088\/jcp.v69n1009.","DOI":"10.4088\/jcp.v69n1009"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25. doi: 10.1186\/s40345-018-0133-9.","DOI":"10.1186\/s40345-018-0133-9"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Judd LL, Akiskal HS, Schettler PJ et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003;73(1\u20132):19\u201332. doi: 10.1016\/s0165-0327(02)00324-5.","DOI":"10.1016\/s0165-0327(02)00324-5"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Ermis C, Taipale H, Tanskanen A et al. Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: a within-subject analysis in a Swedish nationwide cohort. Lancet Psychiatry. 2025;12(3):198\u2013207. doi: 10.1016\/s2215-0366(24)00411-5.","DOI":"10.1016\/s2215-0366(24)00411-5"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Singh B. Lithium for depression-related hospitalisation in bipolar disorder. Lancet Psychiatry. 2025;12(3):165\u2013166. doi: 10.1016\/s2215-0366(25)00026-4.","DOI":"10.1016\/s2215-0366(25)00026-4"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Yocum AK, Singh B. Global trends in the use of pharmacotherapy for the treatment of bipolar disorder. Curr Psychiatry Rep. 2025;27(5):239\u2013247. doi: 10.1007\/s11920-025-01606-8.","DOI":"10.1007\/s11920-025-01606-8"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Singh B, Yocum AK, Strawbridge R et al. Patterns of pharmacotherapy for bipolar disorder: a GBC survey. Bipolar Disord. 2024;26(1):22\u201332. doi: 10.1111\/bdi.13366.","DOI":"10.1111\/bdi.13366"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Atag\u00fcn M, \u015e\u0131ko\u011flu EM, Can SS et al. Neurochemical differences between bipolar disorder type I and II in superior temporal cortices: a proton magnetic resonance spectroscopy study. J Affect Disord. 2018;235:15\u201319. doi: 10.1016\/j.jad.2018.04.010.","DOI":"10.1016\/j.jad.2018.04.010"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research. 1997;73(3):159\u2013171. doi: 10.1016\/s0165-1781(97)00123-6.","DOI":"10.1016\/s0165-1781(97)00123-6"},{"key":"ref44","unstructured":"Guy W. Rockville, MD: National Institute of Mental Health; 1976. ECDEU assessment manual for psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM) pp. 176\u2013338."},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362. doi: 10.1136\/jnnp.23.1.56.","DOI":"10.1136\/jnnp.23.1.56"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Williams JB. A structured interview guide for the hamilton depression rating scale. Arch Gen Psychiatry. 1988;45(8):742\u20137. doi: 10.1001\/archpsyc.1988.01800320058007.","DOI":"10.1001\/archpsyc.1988.01800320058007"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139. doi: 10.1192\/bjp.134.4.382.","DOI":"10.1192\/bjp.134.4.382"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u2013435. doi: 10.1192\/bjp.133.5.429.","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:43Z","timestamp":1791315223000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/systematic-review-of-second-generation-antidepressant-monotherapy-for-acute-bipolar-ii-depression\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4545","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}